Literature DB >> 1270556

A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.

K Chan, N E Williams, J D Baty, T N Calvey.   

Abstract

A sensitive and selective analytical method was used to measure the concentration of neostigmine and pyridostigmine in human plasma. The procedure involved preliminary ion-pair extraction of the drugs into dichloromethane, followed by concentration and anlysis of the ion-pair complex using a gas-liquid chromatographic system fitted with a nitrogen detector. Using the peak area ratio technique, pyridostigmine bromide was used as the internal standard for the quantitation of neostigmine in plasma; neostigmine bromide was the internal marker for the determination of pyridostigmine. The method depends on the thermal dequaternisation of the quaternary amines, and can be used to detect 5 ng/ml in a 3-ml plasma sample. Accurate measurement can be made at levels of 50-1000 ng/ml. This assay procedure has been applied to the separate determination of the plasma concentration of neostigmine and pyridostigmine after single administration of intravenous doses in aneasthetised patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1270556     DOI: 10.1016/s0021-9673(76)80012-x

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

1.  Pharmacokinetics and pharmacological effects of neostigmine in man.

Authors:  T N Calvey; M Wareing; N E Williams; K Chan
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

2.  A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; J Hultman; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

4.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

5.  The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.

Authors:  S C Davison; N M Hyman; A Dehghan; K Chan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

6.  Kinetics of intravenous pyridostigmine in man.

Authors:  T N Calvey; K Chan; A Dehghan; N E Williams
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

7.  Pyridostigmine in human breast milk.

Authors:  L I Hardell; B Lindström; G Lönnerholm; P O Osterman
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

8.  Plasma clearance of neostigmine and pyridostigmine in the dog.

Authors:  P R Baker; T N Calvey; K Chan; C M Macnee; K Taylor
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

9.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

10.  Orthogonal projection to latent structures and first derivative for manipulation of PLSR and SVR chemometric models' prediction: A case study.

Authors:  Fatma F Abdallah; Hany W Darwish; Ibrahim A Darwish; Ibrahim A Naguib
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.